Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Definitive Fractionated Re-irradiation for Local Recurrence Following Stereotactic Body Radiotherapy for Primary Lung Cancer

TADAMASA YOSHITAKE, YOSHIYUKI SHIOYAMA, KATSUMASA NAKAMURA, TOMONARI SASAKI, SAIJI OHGA, MAKOTO SHINOTO, KOTARO TERASHIMA, KAORI ASAI, KEIJI MATSUMOTO, HIDEKI HIRATA and HIROSHI HONDA
Anticancer Research December 2013, 33 (12) 5649-5653;
TADAMASA YOSHITAKE
1Department of Comprehensive Clinical Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yoshitake@radiol.med.kyushu-u.ac.jp
YOSHIYUKI SHIOYAMA
2Department of Heavy Particle Therapy and Radiation Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KATSUMASA NAKAMURA
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOMONARI SASAKI
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SAIJI OHGA
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MAKOTO SHINOTO
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KOTARO TERASHIMA
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAORI ASAI
2Department of Heavy Particle Therapy and Radiation Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEIJI MATSUMOTO
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEKI HIRATA
4Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI HONDA
3Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Aim: To retrospectively evaluate the efficacy and safety of definitive fractionated re-irradiation for local recurrence following stereotactic body radiotherapy (SBRT) for primary lung cancer. Patients and Methods: Between April 2003 and December 2011, 398 patients with primary lung tumor underwent SBRT at the Kyushu University Hospital, and 46 out of these developed local recurrence after SBRT. Definitive fractionated re-irradiation was performed for 17 out of the 46 patients. The median dose of re-irradiation was 60 Gy/ 30 fractions. Concurrent chemotherapy was given to four patients. Results: The median follow-up duration was 12.6 months. At one year post-re-irradiation, local progression-free survival was 33.8%; progression-free survival, 30.9%; cause-specific survival, 79.3%; and overall survival, 74.7%. No severe adverse events were observed during the follow-up. Conclusion: Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.

  • Lung cancer
  • stereotactic body radiotherapy
  • re-irradiation
  • fractionation

Stereotactic body radiotherapy (SBRT) has been used to treat primary and metastatic lung tumors with excellent local control rates. The 3-year local control rate of SBRT for stage I non-small cell lung cancer has been reported to be 78-92% (1-10). However, therapeutic strategies for local recurrence following SBRT have not yet been established. Because most patients who are treated with SBRT are medically-inoperable for various reasons prior to SBRT, surgical resection or chemotherapy for local recurrence is not indicated, in most cases. Severe adverse events due to re-irradiation to the same site have been a concern, but a number of researchers have reported that palliative and definitive re-irradiation following fractionated radiotherapy for primary and metastatic lung tumors was safe and effective (11-16). The efficacy of fractionated re-irradiation for local recurrence following SBRT, in contrast, is still unknown.

The purpose of the present study was to explore the efficacy and safety of definitive fractionated re-irradiation for local recurrence following SBRT for primary lung cancers.

Patients and Methods

Patients' and tumor characteristics. Between April 2004 and December 2011, 398 patients with primary lung cancer underwent SBRT at the Kyushu University Hospital; 46 out of these patients (11.6%) subsequently developed local recurrence. Among these 46 patients, definitive fractionated re-irradiation was performed for 17 patients (37.0%) who were medically-inoperable or refused surgery. The median age of the 17 patients was 81 years (range=69-88 years). Fifteen patients were males, and two were females. The median size of the recurrent tumors was 41 mm (range=19-77 mm). Three patients had regional lymph node metastases and one had brain metastases. Three out of the 17 patients had regional nodal failure and one had two brain metastases, concurrently. Patients' and tumor characteristics are summarized in Table I.

Prior SBRT. The SBRT technique has been described (17). All patients were fixed with a Body Cast System composed of a thermoplastic body cast, a vacuum pillow, arm and leg support, and a carbon plate (Engineering Systems Co., Matsumoto, Japan). Computed tomography (CT) scans were performed at 2-mm intervals on the day of planning and on the first treatment day for verification of the set-up. Treatment planning was performed using the 3D RTP machine (Eclipse: Varian Medical Systems, Palo Alto, CA, USA). The gross tumor volume (GTV) was identified on relevant lung setting CT images. The internal target volume (ITV) was created individually according to the internal respiratory motion. The planning target volume (PTV) margin was 5 mm in all directions. Seven to eight multi-leaf-collimator (MLC)-shaped non-coplanar static ports of 4 or 6 MV X-rays were selected to reduce the percentage of total lung receiving more than 20 Gy (V20) to below 20% (Figure 1A). The prescribed dose was 48 Gy in four fractions, except for one patient (60 Gy in 10 fractions). When the range of respiratory tumor motion was 1 cm or more, irradiation was performed during breath-holding using a visual feedback-guided breath-holding system (18). No patients received chemotherapy before or after SBRT. No severe adverse events (i.e. grade 2 or greater) were observed after SBRT in any patient.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patients' and tumor characteristics.

Fractionated re-irradiation. The length of time from the SBRT to recurrence and to re-irradiation was 4.8-32.9 months (median=11.6 months) and 6.3-35.5 months (median=12.4 months), respectively. Local recurrence was diagnosed by histological or cytological examination in five out of the 17 patients, and by clinical and radiological findings in 12 patients. Definitive fractionated re-irradiation was performed with a dose of 60-70 Gy in 30-35 fractions (median=60 Gy in 30 fractions). The irradiation fields were limited to the recurrent gross tumors without prophylactic lymph node coverage (Figure 1B).

One patient with brain metastases underwent stereotactic radiosurgery prior to re-irradiation to the local recurrence. The lung V20 values of the 17 patients were 3.9%-25.2% (median=9.2%). The cumulative dose (BED10) of the prior SBRT and fractionated re-irradiation ranged from 168 to 189.6 Gy (median=177.6 Gy). Four out of 17 patients (23.5%) received concurrent chemotherapy (carboplatin plus paclitaxel: n=3; S-1: n=1) with fractionated re-irradiation. One patient (5.9%) received hyperthermia treatment weekly during the radiotherapy. Thirteen patients (76.5%) were treated with radiotherapy alone.

Patient follow-up and evaluation. After the completion of re-irradiation, patients were assessed by examinations including chest X-ray and CT every four weeks for the first six months, every 2-3 months for the next 18 months, and every six months thereafter. Brain magnetic resonance imaging (MRI) and fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) were also performed, if needed.

Data analysis. We evaluated the patients' survival rates after re-irradiation, the pattern of failures, and toxicities. Overall survival (OS), cause-specific survival (CSS), progression-free survival (PFS), and local progression-free survival (LPFS) rates were estimated with the Kaplan–Meier method. Toxicities were graded according to the Common Toxicity Criteria for Adverse Effect version 3.0 (CTCAE v3.0) (19).

Results

Survival and patterns of failure. The median follow-up was 12.6 months (range=4.3-31.1 months). Re-recurrence was observed in 11 patients (64.7%). Local re-recurrence was observed in nine patients (52.9%), one patient with local re-recurrence had lung metastasis also. Regional failure and pleural dissemination were each observed in one patient (5.9%). Nine patients (52.9%) died of recurrence, and two (11.8%) died from other diseases.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A computed tomographic (CT) image of a 79-year-old male with cT1aN0M0 squamous cell lung carcinoma of the lower right lobe. A: Stereotactic body radiotherapy (SBRT) was performed for primary lung cancer with a dose of 48 Gy in four fractions. B: Re-irradiation with doses of 60 Gy in 30 fractions was performed for local recurrence which was confirmed by CT-guided biopsy 14 months after SBRT. The patient died of another disease one year after re-irradiation, without disease progression.

At one year post-re-irradiation, the following rates were obtained for the 17 patients: LPFS, 33.8%; PFS, 30.9%; CSS, 79.3%; and OS, 74.7% (Figure 2). The median LPFS was 11.7 months; that for PFS was 9.7, for CSS, 19.0, and for OS, 17.0 months.

Adverse effects. One patient had a grade 2 rib fracture. No other adverse events of grade 2 or more were observed in any patient during the follow-up.

Discussion

In this study, the LPFS rate at one year after fractionated re-irradiation was 33.8%, an unacceptably low value. Two reasons may account for the low LPFS; the first is an insufficient dose of fractionated re-irradiation. The biological effective dose of 60 Gy in 30 fractions is smaller than that of 48 Gy in four fractions. In addition, the recurrent tumor might contain potentially radioresistant cells that survived prior SBRT. The second reason is that the recurrent tumor and the surrounding normal tissue might exhibit hypoxic changes due to microvascular dysfunction as a late effect of the prior radiotherapy (20, 21). In this respect, however, fractionated irradiation takes better advantage of the re-oxygenation phenomenon compared to hypofractionated irradiation, which may be reason for long-term local control being observed in only a few of our patients. Further investigation to determine the optimal dose and fractionation is necessary.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Survival curves after definitive fractionated re-irradiation. This Figure shows Kaplan–Meier curves for the overall survival rate (OS), cause-specific survival rate (CSS), progression-free survival rate (PFS), and local progression-free survival rate (LPFS) of patients after re-irradiation for local recurrence following stereotactic body radiotherapy.

To our knowledge, this is the first report of the feasibility of re-irradiation for local recurrence after SBRT. In previous studies of re-irradiation following fractionated irradiation (12-16), the incidences of grade 2 and 3 radiation pneumonitis were 3%-35% and 0%-21%, and those of esophagitis were 0%-24% and 0%-6%. There were no cases of grade 2 or more esophagitis in this study, unlike previous studies. We suspect that the reasons for the low incidence of esophagitis are that the irradiation dose to the esophagus was very low in the prior SBRT, and that the field of re-irradiation did not include a prophylactic area. In addition, no grade 2 or more pneumonitis was observed in the present study. One of the reasons is probably that none of the patients had severe radiation pneumonitis after the prior SBRT. If the patients had had severe radiation pneumonitis, re-irradiation would not have been performed. This selection bias was one of the limitations of this study.

The single patient who had a rib fracture received medication without surgical treatment and improved. For all these reasons, fractionated re-irradiation may be a safe treatment option for local recurrence following SBRT. However, if the disease in the patients is initially operable, we need to consider the indications for salvage lung resection prior to re-irradiation. Chen et al. reported that salvage surgical resection was feasible after SBRT in patients with initially operable disease (22). In addition, when a patient is epidermal growth factor receptor (EGFR) mutation-positive, re-irradiation can be avoided by using an EGFR-tyrosine kinase inhibitor as a salvage treatment.

In the present study, we used a median dose of 48 Gy with four fractions, which is the most frequently used schedule of SBRT in Japan for primary lung cancer (23). This dose is smaller than the doses used in the U.S.A. (24). The efficacy and safety of re-irradiation after higher doses should be evaluated.

In the present study, the median LPFS was 11.7 months, and long-term local control was obtained in a few patients. The adverse events are considered acceptable. Therefore, when other treatment methods are difficult to perform, fractionated re-irradiation may be an alternative. To improve the treatment results of re-irradiation for local recurrence after SBRT, dose escalation of fractionated re-irradiation, combinations of chemotherapy, and re-irradiation using an SBRT technique may be effective. To decide the optimal treatment strategy for local recurrence after SBRT, a greater number of patients and prospective randomized trials are necessary.

Conclusion

Definitive fractionated re-irradiation is thought to be a safe alternative therapy for local recurrence following SBRT, although its efficacy may be not entirely satisfactory.

Acknowledgements

This work was supported in part by JSPS KAKENHI grant numbers 23390302, 23659589.

  • Received July 20, 2013.
  • Revision received October 24, 2013.
  • Accepted October 28, 2013.
  • Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Matsuo Y,
    2. Shibuya K,
    3. Nagata Y,
    4. Takayama K,
    5. Norihisa Y,
    6. Mizowaki T,
    7. Narabayashi M,
    8. Sakanaka K,
    9. Hiraoka M
    : Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 79: 1104-1111, 2011.
    OpenUrlCrossRefPubMed
    1. Onishi H,
    2. Araki T,
    3. Shirato H,
    4. Nagata Y,
    5. Hiraoka M,
    6. Gomi K,
    7. Yamashita T,
    8. Niibe Y,
    9. Karasawa K,
    10. Hayakawa K,
    11. Takai Y,
    12. Kimura T,
    13. Hirokawa Y,
    14. Takeda A,
    15. Ouchi A,
    16. Hareyama M,
    17. Kokubo M,
    18. Hara R,
    19. Itami J,
    20. Yamada K
    : Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: Clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 101: 1623-1631, 2004.
    OpenUrlCrossRefPubMed
    1. Hoyer M,
    2. Roed H,
    3. Hansen A,
    4. Ohlhuis L,
    5. Petersen J,
    6. Nellemann H,
    7. Berthelsen A,
    8. Grau C,
    9. Engelholm S,
    10. Vondermaase H
    : Prospective study on stereotactic radiotherapy of limited-stage non–small-cell lung cancer. Int J Radiat Oncol Biol Phys 66: S128-S135, 2006.
    OpenUrl
    1. Zimmermann FB,
    2. Geinitz H,
    3. Schill S,
    4. Thamm R,
    5. Nieder C,
    6. Schratzenstaller U,
    7. Molls M
    : Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small cell lung cancer (NSCLC). Acta Oncol 45: 796-801, 2006.
    OpenUrlCrossRefPubMed
    1. Nyman J,
    2. Johansson KA,
    3. Hulten U
    : Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer – mature results for medically inoperable patients. Lung Cancer 51: 97-103, 2006.
    OpenUrlCrossRefPubMed
    1. Koto M,
    2. Takai Y,
    3. Ogawa Y,
    4. Matsushita H,
    5. Takeda K,
    6. Takahashi C,
    7. Britton KR,
    8. Jingu K,
    9. Takai K,
    10. Mitsuya M,
    11. Nemoto K,
    12. Yamada S
    : A phase II study on stereotactic body radiotherapy for stage I non-small cell lung cancer. Radiother Oncol 85: 429-434, 2007.
    OpenUrlCrossRefPubMed
    1. Fakiris AJ,
    2. McGarry RC,
    3. Yiannoutsos CT,
    4. Papiez L,
    5. Williams M,
    6. Henderson MA,
    7. Timmerman R
    : Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75: 677-682, 2009.
    OpenUrlCrossRefPubMed
    1. Ricardi U,
    2. Filippi AR,
    3. Guarneri A,
    4. Giglioli FR,
    5. Ciammella P,
    6. Franco P,
    7. Mantovani C,
    8. Borasio P,
    9. Scagliotti GV,
    10. Ragona R
    : Stereotactic body radiation therapy for early stage non-small cell lung cancer: Results of a prospective trial. Lung Cancer 68: 72-77, 2010.
    OpenUrlCrossRefPubMed
    1. Kopek N,
    2. Paludan M,
    3. Petersen J,
    4. Hansen AT,
    5. Grau C,
    6. Hoyer M
    : Co-morbidity index predicts for mortality after stereotactic body radiotherapy for medically inoperable early-stage non-small cell lung cancer. Radiother Oncol 93: 402-407, 2009.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Baumann P,
    2. Nyman J,
    3. Hoyer M,
    4. Wennberg B,
    5. Gagliardi G,
    6. Lax I,
    7. Drugge N,
    8. Ekberg L,
    9. Friesland S,
    10. Johansson KA,
    11. Lund JA,
    12. Morhed E,
    13. Nilsson K,
    14. Levin N,
    15. Paludan M,
    16. Sederholm C,
    17. Traberg A,
    18. Wittgren L,
    19. Lewensohn R
    : Outcome in a prospective phase II trial of medically inoperable stage I non-small cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27: 3290-3296, 2009.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Morris DE
    : Clinical experience with retreatment for palliation. Semin Radiat Oncol 10: 210-221, 2000.
    OpenUrlPubMed
  4. ↵
    1. Jackson MA,
    2. Ball DL
    : Palliative retreatment of locally-recurrent lung cancer after radical radiotherapy. Med J Aust 147: 391-394, 1987.
    OpenUrlPubMed
    1. Okamoto Y,
    2. Murakami M,
    3. Yoden E,
    4. Sasaki R,
    5. Okuno Y,
    6. Nakajima T,
    7. Kuroda Y
    : Reirradiation for locally recurrent lung cancer previously treated with radiation therapy. Int J Radiat Oncol Biol Phys 52: 390-396, 2002.
    OpenUrlCrossRefPubMed
    1. Wu KL,
    2. Jiang GL,
    3. Qian H,
    4. Wang LJ,
    5. Yang HJ,
    6. Fu XL,
    7. Zhao S
    : Three-dimensional conformal radiotherapy for locoregionally recurrent lung carcinoma after external beam irradiation: A prospective phase I-II clinical trial. Int J Radiat Oncol Biol Phys 57: 1345-1350, 2003.
    OpenUrlPubMed
    1. Gressen EL,
    2. Werner-Wasik M,
    3. Cohn J,
    4. Topham A,
    5. Curran WJ
    : Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 23: 160-163, 2000.
    OpenUrlPubMed
  5. ↵
    1. Jereczek-Fossa BA,
    2. Kowalczyk A,
    3. D'Onofrio A,
    4. Catalano G,
    5. Garibaldi C,
    6. Boboc G,
    7. Vitolo V,
    8. Leonardi MC,
    9. Cambria R,
    10. Orecchia R
    : Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Strahlenther Onkol 184: 36-40, 2008.
    OpenUrlPubMed
  6. ↵
    1. Shioyama Y,
    2. Nakamura K,
    3. Anai S,
    4. Sasaki T,
    5. Ooga S,
    6. Saku M,
    7. Urashima Y,
    8. Yoshitake T,
    9. Toba T,
    10. Terashima H,
    11. Honda H
    : Stereotactic radiotherapy for lung and liver tumors using a body cast system: Setup accuracy and preliminary clinical outcome. Radiat Med 23: 407-413, 2005.
    OpenUrlPubMed
  7. ↵
    1. Yoshitake T,
    2. Shioyama Y,
    3. Nakamura K,
    4. Ohga S,
    5. Nonoshita T,
    6. Ohnishi K,
    7. Terashima K,
    8. Arimura H,
    9. Hirata H,
    10. Honda H
    : A clinical evaluation of visual feedback-guided breath-hold reproducibility of tumor location. Phys Med Biol 54: 7171-7182, 2009.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Trotti A,
    2. Colevas AD,
    3. Setser A,
    4. Rusch V,
    5. Jaques D,
    6. Budach V,
    7. Langer C,
    8. Murphy B,
    9. Cumberlin R,
    10. Coleman CN,
    11. Rubin P
    : CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13: 176-181, 2003.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Vujaskovic Z,
    2. Anscher MS,
    3. Feng QF,
    4. Rabbani ZN,
    5. Amin K,
    6. Samulski TS,
    7. Dewhirst MW,
    8. Haroon ZA
    : Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys 50: 851-855, 2001.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Stone HB,
    2. Coleman CN,
    3. Anscher MS,
    4. McBride WH
    : Effects of radiation on normal tissue: Consequences and mechanisms. Lancet Oncol 4: 529-536, 2003.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Chen FS,
    2. Matsuo Y,
    3. Yoshizawa A,
    4. Sato T,
    5. Sakai H,
    6. Bando T,
    7. Okubo K,
    8. Shibuya K,
    9. Date H
    : Salvage lung resection for non-small cell lung cancer after stereotactic body radiotherapy in initially operable patients. J Thorac Oncol 5: 1999-2002, 2010.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Nagata Y,
    2. Hiraoka M,
    3. Mizowaki T,
    4. Narita Y,
    5. Matsuo Y,
    6. Norihisa Y,
    7. Onishi H,
    8. Shirato H
    : Survey of stereotactic body radiation therapy in Japan by the Japan 3-D Conformal External Beam Radiotherapy Group. Int J Radiat Oncol Biol Phys 75: 343-347, 2009.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Timmerman R,
    2. Paulus R,
    3. Galvin J,
    4. Michalski J,
    5. Straube W,
    6. Bradley J,
    7. Fakiris A,
    8. Bezjak A,
    9. Videtic G,
    10. Johnstone D,
    11. Fowler J,
    12. Gore E,
    13. Choy H
    : Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303: 1070-1076, 2010.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 33 (12)
Anticancer Research
Vol. 33, Issue 12
December 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Definitive Fractionated Re-irradiation for Local Recurrence Following Stereotactic Body Radiotherapy for Primary Lung Cancer
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
8 + 12 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Definitive Fractionated Re-irradiation for Local Recurrence Following Stereotactic Body Radiotherapy for Primary Lung Cancer
TADAMASA YOSHITAKE, YOSHIYUKI SHIOYAMA, KATSUMASA NAKAMURA, TOMONARI SASAKI, SAIJI OHGA, MAKOTO SHINOTO, KOTARO TERASHIMA, KAORI ASAI, KEIJI MATSUMOTO, HIDEKI HIRATA, HIROSHI HONDA
Anticancer Research Dec 2013, 33 (12) 5649-5653;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Definitive Fractionated Re-irradiation for Local Recurrence Following Stereotactic Body Radiotherapy for Primary Lung Cancer
TADAMASA YOSHITAKE, YOSHIYUKI SHIOYAMA, KATSUMASA NAKAMURA, TOMONARI SASAKI, SAIJI OHGA, MAKOTO SHINOTO, KOTARO TERASHIMA, KAORI ASAI, KEIJI MATSUMOTO, HIDEKI HIRATA, HIROSHI HONDA
Anticancer Research Dec 2013, 33 (12) 5649-5653;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Conclusion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma - Prognostic Effect of the AJCC Tumor-Node-Metastasis Clinical Staging System
  • Google Scholar

More in this TOC Section

  • Pelvic Recurrence After Curative Resection for Rectal Adenocarcinoma: Impact of Surgery on Survival
  • Glasgow Prognostic Score Predicts Survival and Recurrence Pattern in Patients With Hepatocellular Carcinoma After Hepatectomy
  • Small Bowel Lipomatosis: An Unusual Radiological Finding in Patients With Renal Cell Cancer on Pazopanib
Show more Clinical Studies

Similar Articles

Keywords

  • Lung cancer
  • Stereotactic body radiotherapy
  • re-irradiation
  • fractionation
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire